8:04 AM ET
8-K
Business Update
Neumora Therapeutics Business Update
Neumora Therapeutics reported third quarter 2026 financial results and provided a pipeline update, including the submission of an IND application for NMRA-215 in obesity. The company reported a cash position of $85.7 million and noted that it will require substantial additional funding to continue operations and complete product development.